Cargando…

Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model

The Wiskott-Aldrich syndrome protein (WASp) is a key regulator of the actin cytoskeleton in hematopoietic cells and mutated in two severe immunodeficiency diseases with high incidence of cancer. Wiskott-Aldrich syndrome (WAS) is caused by loss-of-function mutations in WASp and most frequently associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Keszei, Marton, Kritikou, Joanna S., Sandfort, Deborah, He, Minghui, Oliveira, Mariana M.S., Wurzer, Hannah, Kuiper, Raoul V., Westerberg, Lisa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209425/
https://www.ncbi.nlm.nih.gov/pubmed/30393584
http://dx.doi.org/10.1080/2162402X.2018.1468954
_version_ 1783366911357091840
author Keszei, Marton
Kritikou, Joanna S.
Sandfort, Deborah
He, Minghui
Oliveira, Mariana M.S.
Wurzer, Hannah
Kuiper, Raoul V.
Westerberg, Lisa S.
author_facet Keszei, Marton
Kritikou, Joanna S.
Sandfort, Deborah
He, Minghui
Oliveira, Mariana M.S.
Wurzer, Hannah
Kuiper, Raoul V.
Westerberg, Lisa S.
author_sort Keszei, Marton
collection PubMed
description The Wiskott-Aldrich syndrome protein (WASp) is a key regulator of the actin cytoskeleton in hematopoietic cells and mutated in two severe immunodeficiency diseases with high incidence of cancer. Wiskott-Aldrich syndrome (WAS) is caused by loss-of-function mutations in WASp and most frequently associated with lymphoreticular tumors of poor prognosis. X-linked neuropenia (XLN) is caused by gain-of-function mutations in WASp and associated with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). To understand the role of WASp in tumorigenesis, we bred WASp(+), WASp(−), and WASp-XLN mice onto tumor susceptible p53(+/-) background and sub-lethally irradiated them to enhance tumor development. We followed the cohorts for 24 weeks and tumors were characterized by histology and flow cytometry to define the tumor incidence, onset, and cell origin. We found that p53(+/-)WASp(+) mice developed malignancies, including solid tumors and T cell lymphomas with 71.4% of survival 24 weeks after irradiation. p53(+/-)WASp(−) mice showed lower survival rate and developed various early onset malignancies. Surprisingly, the p53(+/-)WASp-XLN mice developed malignancy mostly with late onset, which caused delayed mortality in this colony. This study provides evidence for that loss-of-function and gain-of-function mutations in WASp influence tumor incidence and onset.
format Online
Article
Text
id pubmed-6209425
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-62094252018-11-02 Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model Keszei, Marton Kritikou, Joanna S. Sandfort, Deborah He, Minghui Oliveira, Mariana M.S. Wurzer, Hannah Kuiper, Raoul V. Westerberg, Lisa S. Oncoimmunology Original Research The Wiskott-Aldrich syndrome protein (WASp) is a key regulator of the actin cytoskeleton in hematopoietic cells and mutated in two severe immunodeficiency diseases with high incidence of cancer. Wiskott-Aldrich syndrome (WAS) is caused by loss-of-function mutations in WASp and most frequently associated with lymphoreticular tumors of poor prognosis. X-linked neuropenia (XLN) is caused by gain-of-function mutations in WASp and associated with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). To understand the role of WASp in tumorigenesis, we bred WASp(+), WASp(−), and WASp-XLN mice onto tumor susceptible p53(+/-) background and sub-lethally irradiated them to enhance tumor development. We followed the cohorts for 24 weeks and tumors were characterized by histology and flow cytometry to define the tumor incidence, onset, and cell origin. We found that p53(+/-)WASp(+) mice developed malignancies, including solid tumors and T cell lymphomas with 71.4% of survival 24 weeks after irradiation. p53(+/-)WASp(−) mice showed lower survival rate and developed various early onset malignancies. Surprisingly, the p53(+/-)WASp-XLN mice developed malignancy mostly with late onset, which caused delayed mortality in this colony. This study provides evidence for that loss-of-function and gain-of-function mutations in WASp influence tumor incidence and onset. Taylor & Francis 2018-07-30 /pmc/articles/PMC6209425/ /pubmed/30393584 http://dx.doi.org/10.1080/2162402X.2018.1468954 Text en © 2018 The Author(s). Published by Taylor & Francis. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Original Research
Keszei, Marton
Kritikou, Joanna S.
Sandfort, Deborah
He, Minghui
Oliveira, Mariana M.S.
Wurzer, Hannah
Kuiper, Raoul V.
Westerberg, Lisa S.
Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model
title Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model
title_full Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model
title_fullStr Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model
title_full_unstemmed Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model
title_short Wiskott-Aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model
title_sort wiskott-aldrich syndrome gene mutations modulate cancer susceptibility in the p53(±) murine model
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209425/
https://www.ncbi.nlm.nih.gov/pubmed/30393584
http://dx.doi.org/10.1080/2162402X.2018.1468954
work_keys_str_mv AT keszeimarton wiskottaldrichsyndromegenemutationsmodulatecancersusceptibilityinthep53murinemodel
AT kritikoujoannas wiskottaldrichsyndromegenemutationsmodulatecancersusceptibilityinthep53murinemodel
AT sandfortdeborah wiskottaldrichsyndromegenemutationsmodulatecancersusceptibilityinthep53murinemodel
AT heminghui wiskottaldrichsyndromegenemutationsmodulatecancersusceptibilityinthep53murinemodel
AT oliveiramarianams wiskottaldrichsyndromegenemutationsmodulatecancersusceptibilityinthep53murinemodel
AT wurzerhannah wiskottaldrichsyndromegenemutationsmodulatecancersusceptibilityinthep53murinemodel
AT kuiperraoulv wiskottaldrichsyndromegenemutationsmodulatecancersusceptibilityinthep53murinemodel
AT westerberglisas wiskottaldrichsyndromegenemutationsmodulatecancersusceptibilityinthep53murinemodel